Pharma Mar Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	221.39	174.86	158.15	196.34	229.83
Revenue Growth (YoY)	26.61%	10.56%	-19.45%	-14.57%	-14.87%
Cost of Revenue	12.26	8.18	9.61	13.64	16.44
Gross Profit	209.13	166.67	148.54	182.7	213.39
Selling, General & Admin	59.38	47.18	41.81	43.24	39.74
Research & Development	95.19	103.5	99.3	83.45	72.17
Other Operating Expenses	-6.15	9.52	11.26	13.94	9.04
Operating Expenses	148.42	160.2	152.37	140.63	120.95
Operating Income	60.72	6.47	-3.83	42.07	92.45
Interest Expense	-2.46	-2.47	-2.42	-2.38	-3.37
Interest & Investment Income	3.44	5.68	4.32	0.88	0.37
Currency Exchange Gain (Loss)	-2.05	2.31	-1.68	3.11	5.67
EBT Excluding Unusual Items	59.65	11.99	-3.61	43.68	95.12
Gain (Loss) on Sale of Investments	-	-	-0.02	-1.89	0.01
Other Unusual Items	-	-	-	2	-
Pretax Income	59.65	11.99	-3.62	43.79	95.13
Income Tax Expense	-15.34	-14.14	-4.76	-5.57	2.27
Earnings From Continuing Operations	74.99	26.13	1.14	49.36	92.86
Net Income to Company	74.99	26.13	1.14	49.36	92.86
Net Income	74.99	26.13	1.14	49.36	92.86
Net Income to Common	74.99	26.13	1.14	49.36	92.86
Net Income Growth	187.03%	2197.71%	-97.70%	-46.85%	-32.35%
Shares Outstanding (Basic)	17	18	18	18	18
Shares Outstanding (Diluted)	17	18	18	18	18
Shares Change (YoY)	-0.62%	-1.98%	-0.81%	-0.12%	-1.31%
EPS (Basic)	4.30	1.49	0.06	2.73	5.14
EPS (Diluted)	4.30	1.49	0.06	2.73	5.13
EPS Growth	188.68%	2382.56%	-97.80%	-46.78%	-31.51%
Free Cash Flow	46.67	-8.99	-28.25	29.47	17.87
Free Cash Flow Per Share	2.67	-0.51	-1.58	1.63	0.99
Dividend Per Share	-	0.800	0.650	0.650	0.650
Dividend Growth	-	23.08%	-	-	8.33%
Gross Margin	94.46%	95.32%	93.92%	93.05%	92.85%
Operating Margin	27.42%	3.70%	-2.42%	21.43%	40.22%
Profit Margin	33.87%	14.94%	0.72%	25.14%	40.40%
Free Cash Flow Margin	21.08%	-5.14%	-17.87%	15.01%	7.78%
EBITDA	66.47	10.07	-1.15	44.88	94.99
EBITDA Margin	30.02%	5.76%	-0.73%	22.86%	41.33%
D&A For EBITDA	5.75	3.6	2.68	2.81	2.54
EBIT	60.72	6.47	-3.83	42.07	92.45
EBIT Margin	27.42%	3.70%	-2.42%	21.43%	40.22%
Effective Tax Rate	-	-	-	-	2.39%
Revenue as Reported	221.39	174.86	158.15	196.34	229.83

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.